Daratumumab (Anti-Human CD38) 是首创的特异性抗 CD38 单克隆抗体。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附，从而增加了 MM 对蛋白酶体抑制的敏感性。
| 生物活性 |
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition. |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| 体外研究 |
Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines. |
||||||||
| 体内研究 |
Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models.
|
||||||||
| CAS号 |
945721-28-8
|
||||||||
| 中文名称 |
达雷妥尤单抗； 达妥木单抗
|
||||||||
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||
| 临床试验 |
|
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet